Breaking News

Almac Completes Commercial API Facility

October 9, 2012

Will be operational by the end of the year

Almac’s expansion of its API manufacturing facility at its European Headquarters in Craigavon, UK has been completed and will be operational by the end of the year.  The expansion includes the installation of two 1,000L reactors and pressure filter dryer, which allows production of GMP API to 150kg batch size.
“Almac’s investment has further demonstrated our goal of being the outsourcing partner of choice through all stages of clinical development,” said Denis Geffroy, vice president of business development. “We are delighted to have the scale to share the manufacturing journey with our clients from preclinical phase to full commercialization.”
The expansion allows clients to leverage Almac’s API and drug product offering at the same site, allowing technology transfer of small molecule and peptide projects from lab development to large-scale manufacture.

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks